FibroBiologics (FBLG) Retained Earnings (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Retained Earnings of $67.9 million for Q2 2026, up 47.64% year-over-year from $46.0 million in Q2 2025, and up 9.96% on a QoQ basis from $61.8 million in Q1 2026.
FibroBiologics (FBLG) Retained Earnings (2022 - 2026) Analysis & Trends
FibroBiologics has reported Retained Earnings for 5 years, with the latest figure at $67.9 million in Q2 2026.
- Retained Earnings for Q2 2026 came in at $67.9 million, up 47.64% year-over-year; the trailing twelve-month figure through Jun 2026 was $67.9 million (up 47.64% YoY), and the FY2025 annual result was $60.3 million, up 57.68% from the prior year.
- Retained Earnings advanced to $67.9 million in Q2 2026, from $61.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $67.9 million in Q2 2026 and troughed at -$32.8 million in Q1 2024.
- A 5-year average of $29.7 million and a median of $40.5 million in 2024 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2023, when Retained Earnings soared 425.32%; it then surged 44.19% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$7.9 million in 2022, then soared by 425.32% to $25.6 million in 2023, then surged by 49.37% to $38.3 million in 2024, then surged by 57.68% to $60.3 million in 2025, then climbed by 12.59% to $67.9 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $67.9 million in Q2 2026, $61.8 million in Q1 2026, and $60.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | 67.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.92 Mn |
| Mar 31, 2026 | 61.76 Mn |
| Dec 31, 2025 | 60.32 Mn |
| Sep 30, 2025 | 51.05 Mn |
| Jun 30, 2025 | -45.10 Mn |
| Mar 31, 2025 | -40.48 Mn |
| Dec 31, 2024 | -35.52 Mn |
| Sep 30, 2024 | 35.16 Mn |
| Jun 30, 2024 | -31.92 Mn |
| Mar 31, 2024 | -32.82 Mn |
| Dec 31, 2023 | -24.36 Mn |
| Dec 31, 2022 | -7.87 Mn |